(Press-News.org) The German Institute for Quality and Efficiency in Health Care (IQWiG) reassessed the antiviral drug combination rilpivirine/emtricitabine/tenofovir. In early 2012, the combination was approved for the treatment of adults infected with human immunodeficiency virus type 1 (HIV-1) who have not received previous antiretroviral treatment. For men, the Institute then found proof, and for women, indications of a considerable added benefit of the fixed combination in comparison with the appropriate comparator therapy.
In the end of 2013, the approval was expanded to people with previous antiretroviral treatment, and the drug manufacturer submitted a dossier for this new therapeutic indication, in which it claimed an added benefit again. IQWiG came to a different conclusion: The only study cited in the dossier was too short for the assessment of an added benefit, and the appropriate comparator therapy was not implemented. Hence an added benefit of rilpivirine/emtricitabine/tenofovir in the treatment of adults infected with HIV-1 with previous antiretroviral treatment is not proven.
New therapeutic indication, new comparator therapy
According to the expansion of approval from November 2013, the fixed drug combination can now also be used in HIV-1 infected adults with a viral load of no more than 100,000 RNA copies per millilitre who have already received antiretroviral treatment – provided that their virus has no mutations associated with known resistance to the drugs.
Since these patients had already received antiretroviral treatment, which possibly did not have a satisfactory effect or had to be discontinued, the Federal Joint Committee (G-BA) specified a different appropriate comparator therapy than in 2012 for non-pretreated patients: Antiretroviral treatment was now to be specified individually, depending on the previous treatment and the reason for treatment switching, e.g. treatment failure or side effects.
Comparator therapy not implemented
In its dossier, the manufacturer presented one single study, in which the drug combination was compared with an individual antiretroviral treatment. However, no switch of treatment was possible in the control group. Instead, the patients continued their previous treatment – although approximately 10% of them complained of side effects in the beginning, and about 20% claimed to be worried about longterm side effects of their previous treatment.
Randomized controlled phase far too short
Moreover, the rilpivirine/emtricitabine/tenofovir combination was only compared with the appropriate comparator therapy for 24 weeks in the study. But the research question of the benefit assessment cannot be answered on the basis of such a short study; this would require at least one to two years.
For these reasons, an added benefit of rilpivirine/emtricitabine/tenofovir is not proven for HIV-1 infected adults with previous antiretroviral treatment whose viruses do not have mutations associated with resistance.
G-BA decides on the extent of added benefit
The dossier assessment is part of the overall procedure for early benefit assessments supervised by the G-BA. After publication of the manufacturer's dossier and IQWiG's assessment, the G-BA conducts a commenting procedure, which may provide further information and result in a change to the benefit assessment. The G BA then decides on the extent of the added benefit, thus completing the early benefit assessment.
An overview of the results of IQWiG's benefit assessment is given by a German-language executive summary. In addition, the website » http://www.gesundheitsinformation.de, published by IQWiG, provides easily understandable and brief German-language information on rilpivirine/emtricitabine/tenofovir.
The G-BA website contains both general English-language information on benefit assessment pursuant to §35a Social Code Book (SGB) V and specific German-language information on the assessment of rilpivirine/emtricitabine/tenofovir. More English-language information will be available soon (Sections 2.1 to 2.6 of the dossier assessment as well as subsequently published health information on » http://www.informedhealthonline.org).
If you would like to be informed when these documents are available, please send an e-mail to » email@example.com.
Dr. Anna-Sabine Ernst
Institute for Quality and Efficiency in Health Care
Sprawdź aktualny ranking najlepszych kredytów mieszkaniowych w Polsce - atrakcyjne kredytowanie nieruchomości.
Rilpivirine combination product in pretreated HIV-1 patients: added benefit not proven
Only study cited in the dossier was too short / appropriate comparator therapy not implemented
ELSE PRESS RELEASES FROM THIS DATE:
Tropical Cyclone Peipah passed the island of Palau on April 5 moving through the Northwestern Pacific Ocean as it heads for a landfall in the Philippines. Peipah was formerly known as Tropical Cyclone 05W and was renamed when it reached tropical storm-force. Since then, however, wind shear has weakened the storm to a tropical depression. On April 5 at 2100 UTC/5 p.m. EDT, Tropical Storm 05W, renamed Peipah (and known locally in the Philippines as Domeng) was located about 262 nautical miles east-southeast of Koror. It was centered near 5.5 north and 137.8 east and moving ...
UC Davis School of Veterinary Medicine researchers have identified the genetic mutation responsible for a form of cleft palate in the dog breed Nova Scotia Duck Tolling Retrievers. They hope that the discovery, which provides the first dog model for the craniofacial defect, will lead to a better understanding of cleft palate in humans. Although cleft palate is one of the most common birth defects in children, affecting approximately one in 1,500 live human births in the United States, it is not completely understood. The findings appear this week online in the journal ...
CHESTNUT HILL, MA (April 7, 2014) – Taking remedial courses at the four-year college level may hold students back from earning their bachelor's degrees, but at the community college level remedial education can help earn an associate's degree, according to researchers from Boston College's Lynch School of Education. The role of remedial education has been under scrutiny for years, viewed as an essential tool in efforts to raise rates of degree completion. At the same time, critics question whether the courses are appropriate for institutions of higher education. The ...
When we watch a movie, our brains react to it immediately in a way similar to brains of other people. Researchers at Aalto University in Finland have succeeded in developing a method fast enough to observe immediate changes in the function of the brain even when watching a movie. By employing movies it was possible to investigate the function of the human brain in experimental conditions that are close to natural. Traditionally, in neuroscience research, simple stimuli, such as checkerboard patterns or single images, have been used. Viewing a movie creates multilevel ...
As part of a German-French research project, a team led by Dr. Christa E. Müller from the University of Bonn and Dr. David Blum from the University of Lille was able to demonstrate for the first time that caffeine has a positive effect on tau deposits in Alzheimer's disease. The two-years project was supported with 30,000 Euro from the non-profit Alzheimer Forschung Initiative e.V. (AFI) and with 50,000 Euro from the French Partner organization LECMA. The initial results were published in the online edition of the journal "Neurobiology of Aging." Tau deposits, along ...
Researchers are blending technology with nature, as they present details on an iPad application to examine how young children are learning science skills in nature-themed outdoor play settings. Alan Wight, a doctoral candidate in the University of Cincinnati School of Education; Cathy Maltbie, a research associate for the UC Evaluation Services Center; and Victoria Carr, a UC associate professor of education and director of the UC Arlitt Child and Family Research and Education Center, presented details on the innovation at the annual meeting of the American Educational ...
SAN DIEGO – (April 7th, 2014) A major discovery that brings a new drug target to the increasingly exciting landscape of cancer immunotherapy was published yesterday by researchers from La Jolla Institute for Allergy and Immunology and their collaborators from other institutes. The study, led by Amnon Altman, Ph.D., and Kok-Fai Kong, Ph.D., is particularly noteworthy because it reveals a new way to block the function of CTLA-4, an immune inhibitory checkpoint receptor already generating huge interest in the pharmaceutical and research communities due to its potential ...
An international team of researchers from the University of Arizona, China and the United Kingdom has discovered the earliest known cardiovascular system, and the first to clearly show a sophisticated system complete with heart and blood vessels, in fossilized remains of an extinct marine creature that lived over half a billion years ago. The finding sheds new light on the evolution of body organization in the animal kingdom and shows that even the earliest creatures had internal organizational systems that strongly resemble those found in their modern descendants. "This ...
JUPITER, FL, April 7, 2014 – Scientists thought they basically knew how the most common drugs used to treat type 2 diabetes worked, but a new study from the Florida campus of The Scripps Research Institute (TSRI) reveals unexpected new aspects of the process. These findings could eventually lead to more potent anti-diabetic drugs with fewer serious side effects. The study was published in the April 7, 2014 issue of the journal Nature Communications. The most common type 2 diabetes treatments are known as insulin-sensitizing drugs, which improve how the body responds ...
Drew Reynolds and Sean Nickerson, founding partners of TrackResults, which specializes in Business Intelligence, Sales Reporting and Digital Manifesting for the timeshare industry, have joined the ranks of key ARDA leadership by receiving the coveted RRP designation. The American Resort Development Association (ARDA) is the Washington D.C.-based trade association representing the vacation ownership and resort development industries (timeshares). ARDA has almost 1,000 corporate members ranging from privately held firms to publicly traded corporations with extensive experience ...